Physician

Adam Louis Schreiber, D.O.

According to 2025 Medicare claims, Adam Schreiber, D.O. (NPI: 1831313352) practices physical medicine and rehabilitation in the Camden, NJ market, with the plurality of this provider's patient population coming from Camden, NJ. This provider's primary affiliated billing organization is PREMIER BRAIN AND SPINE, LLC (NPI: 1922771377; TIN: 871737086) and primary practice location at 08080-9229.

Schreiber's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 906 traditional Medicare patients, billed 7,413 HCPCS/CPT codes, and received $327,473 in Medicare payments. The top billing code was G0480 (Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms). Part D data shows 3,849 prescription claims across 583 beneficiaries totaling $291,815 in drug costs, led by Relistor (Methylnaltrexone Bromide). Open Payments data shows 84 records totaling $1,248. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $90,933 and ending at $327,473. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $57,846 and ending at $291,815. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	464	1,444	$90,933
2016	708	2,913	$244,891
2017	448	2,310	$187,655
2018	N/R	N/R	N/R
2019	13	22	$1,216
2020	16	27	$1,674
2021	343	914	$74,044
2022	924	6,174	$400,400
2023	916	5,123	$353,012
2024	906	7,413	$327,473

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	187	520	$57,846
2016	575	1,840	$279,233
2017	398	1,712	$213,409
2018	60	133	$7,249
2019	46	91	$1,608
2020	50	103	$1,420
2021	310	680	$53,483
2022	903	4,347	$402,459
2023	745	3,563	$400,565
2024	583	3,849	$291,815

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms	177	289	$111
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	393	601	$94
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	760	2,182	$66
80307	Testing for presence of drug, by chemistry analyzers	214	347	$60
99484	Care management services for behavioral health conditions, 20 minutes or more clinical staff time directed by health care professional	399	544	$46

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Relistor	Methylnaltrexone Bromide	21	750	$55,650
Belbuca	Buprenorphine Hcl	79	2,370	$50,062
Oxycontin	Oxycodone Hcl	54	1,602	$20,199
Ztlido	Lidocaine	28	900	$19,588
Lidocaine	Lidocaine	121	3,738	$17,579

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	84	$1,248	Collegium Pharmaceutical, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Adam Louis Schreiber, D.O.?

Tedicare shows public-source Medicare data for Adam Louis Schreiber, D.O. (NPI 1831313352), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Adam Louis Schreiber, D.O. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Adam Louis Schreiber, D.O.?

Adam Louis Schreiber, D.O. is linked to PREMIER BRAIN AND SPINE, LLC (billing NPI 1922771377) in the available physician profile data.

Does Adam Louis Schreiber, D.O. have Open Payments data?

Adam Louis Schreiber, D.O. has 84 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.